Pembrolizumab Combination With Lenvatinib in Pts With Recurrent,Persistent,Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surgery or Radiotherapy

This study is testing the combination of pembrolizumab (an immunotherapy drug) and lenvatinib (a targeted therapy) for women with advanced, recurrent, or metastatic vulvar squamous cell carcinoma — a type of cancer affecting the external female genitalia — that cannot be removed with surgery or treated with curative radiation. **You may be eligible if...** - You are a woman 18 or older - You have confirmed locally advanced, recurrent, persistent, or metastatic vulvar squamous cell carcinoma - Surgery or curative radiation is not an option - You have had no more than 2 prior lines of chemotherapy for recurrent or metastatic disease - You have measurable disease on imaging - Your general health is good (ECOG status 0–1) **You may NOT be eligible if...** - You have had more than 2 prior chemotherapy regimens for advanced disease - You have poorly controlled heart disease or other serious conditions - You are pregnant or breastfeeding - You have significant side effects still ongoing from previous treatments Talk to your doctor to see if this trial is right for you.